Converted by EDGARwiz

NOVOGEN LIMITED

(ASX: NRT)

[f131105asxcleansingnotice002.gif]

ASX RELEASE

5 November 2013

CLEANSING NOTICE

We refer to the issue of a convertible security by Novogen Limited (Novogen) on 5 July 2013.

Pursuant to a notice of conversion of a portion of the convertible security representing in aggregate

$75,000, Novogen issued 506,757 ordinary shares to Merrill Lynch (Australia) Nominees Pty

Limited ACN 003 925 031 FBO Hudson Bay Master Fund Limited on 5 November 2013 (Shares).

For the purposes of section 708A(5)(e)(i) of the Corporations Act 2001 (Cth) (Corporations Act)

Novogen gives notice that:

Novogen issued the Shares without disclosure to investors under Part 6D.2 of the

Corporations Act;

as at the date of this notice, Novogen has complied with:

(a) the provisions of Chapter 2M of the Corporations Act as they apply to Novogen;

and

(b) section 674 of the Corporations Act; and

as at the date of this notice, there is no information that is “excluded information” (as

defined in subsections 708A(7) and 708A(8) of the Corporations Act) which is required

to be disclosed by Novogen.

[f131105asxcleansingnotice004.gif]

Yours faithfully,

Lionel Mateo

Company Secretary

NOVOGEN LTD – ACN 063 259 754

16-20 Edgeworth David Ave, Hornsby, NSW, 2077

P: +61 (0) 2 9476 0344 - F: +61 (0) 2 9476 0388

www.novogen.com

Appendix 3B

New issue announcement

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement,

application for quotation of additional securities

and agreement

Information or documents not available now must be given to ASX as soon as available. Information and

documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,

04/03/13

Name of entity

Novogen Limited (“Novogen”)

ABN

37 063 259 754

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

⁺Class of⁺securities issued or to Ordinary Fully paid share (Share)

be issued

Number of +securities issued or 506,757 fully-paid Shares

to be issued (if known) or

maximum number which may

be issued

Principal

terms

the Fully-paid ordinary voting shares

+securities (e.g. if options, Ranks pari passu with all existing Ordinary Shares

exercise price and expiry date; if

partly paid +securities, the

amount outstanding and due

dates

for

payment;

+convertible

securities,

the

conversion price and dates for

conversion)

+ See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 1

Appendix 3B

New issue announcement

Do the +securities rank equally All the shares referred to in item 2 will rank

in all respects from the +issue pari passu with all existing Ordinary Shares

date with an existing +class of

quoted +securities?

If the additional +securities do

not rank equally, please state:

 the date from which they do

 the extent to which they

participate for the next

dividend, (in the case of a

trust,

distribution)

interest payment

 the extent to which they do

not rank equally, other than

in relation to the next

dividend, distribution or

interest payment

Issue price or consideration

Issue price per Share is $0.148

Purpose of the issue

The Shares referred to in the item 2 are issued

(If issued as consideration for pursuant to a conversion notice received under the

the acquisition of assets, clearly Convertible Securities Agreement announced to the

identify those assets)

market on 4 July 2013

Is the entity an +eligible entity No

that has obtained security

holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h

in relation to the +securities the

subject of this Appendix 3B, and

comply with section 6i

The date the security holder N/A

resolution under rule 7.1A was

passed

Number of +securities issued 506,757 fully-paid Shares

without security holder approval

under rule 7.1

+ See chapter 19 for defined terms.

Appendix 3B Page 2

04/03/2013

Appendix 3B

New issue announcement

Number of +securities issued N/A

with security holder approval

under rule 7.1A

Number of +securities issued N/A

with security holder approval

under rule 7.3, or another

specific security holder approval

(specify date of meeting)

Number of +securities issued N/A

under an exception in rule 7.2

If +securities issued under rule N/A

7.1A, was issue price at least 75%

of 15 day VWAP as calculated

under rule 7.1A.3? Include the

+issue date and both values.

Include the source of the VWAP

calculation.

If +securities were issued under N/A

rule

7.1A

for

non-cash

consideration, state date on

which

valuation

consideration was released to

ASX Market Announcements

Calculate the entity’s remaining N/A

issue capacity under rule 7.1 and

rule 7.1A – complete Annexure 1

and release to ASX Market

Announcements

+Issue dates

5 November 2013

Note: The issue date may be prescribed by

ASX (refer to the definition of issue date in

rule 19.12). For example, the issue date for a

pro rata entitlement issue must comply with

the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

Number

⁺Class

Number and

⁺class of all 145,466,852

Ordinary Shares

⁺securities quoted on ASX

(including the⁺securities in

section 2 if applicable)

+ See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 3

Appendix 3B

New issue announcement

Number

⁺Class

Number and

⁺class of all 6,007,216

Unlisted options with

⁺securities not quoted on ASX

various exercise dates

(including the⁺securities in

and prices.

section 2 if applicable)

Unlisted

convertible

note with a face value of

$1,255,000

60,000,000

Unlisted

convertible

notes, with face values

of $1,500,000

Dividend policy (in the case of a N/A

trust, distribution policy) on the

increased capital (interests)

Part 2 - Pro rata issue

Is security holder approval N/A

required?

Is the issue renounceable or non- N/A

renounceable?

Ratio in which the⁺securities N/A

will be offered

⁺Class of⁺securities to which the N/A

offer relates

⁺Record date to determine N/A

entitlements

Will holdings on different N/A

registers (or subregisters) be

aggregated

for

calculating

entitlements?

Policy for deciding entitlements N/A

in relation to fractions

+ See chapter 19 for defined terms.

Appendix 3B Page 4

04/03/2013

Appendix 3B

New issue announcement

Names of countries in which the N/A

entity has security holders who

will not be sent new offer

documents

Note: Security holders must be told how their

entitlements are to be dealt with.

Cross reference: rule 7.7.

Closing date for receipt of N/A

acceptances or renunciations

+ See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 5

Appendix 3B

New issue announcement

Names of any underwriters

N/A

Amount of any underwriting fee N/A

or commission

Names of any brokers to the N/A

issue

Fee or commission payable to the N/A

broker to the issue

Amount of any handling fee N/A

payable to brokers who lodge

acceptances or renunciations on

behalf of security holders

If the issue is contingent on N/A

security holders’ approval, the

date of the meeting

Date entitlement and acceptance N/A

form and offer documents will be

sent to persons entitled

If the entity has issued options, N/A

and the terms entitle option

holders

participate

exercise, the date on which

notices will be sent to option

holders

Date rights trading will begin (if N/A

applicable)

Date rights trading will end (if N/A

applicable)

How do security holders sell N/A

their entitlements in full through

a broker?

How do security holders sell part N/A

of their entitlements through a

broker and accept for the

balance?

+ See chapter 19 for defined terms.

Appendix 3B Page 6

04/03/2013

Appendix 3B

New issue announcement

How do security holders dispose N/A

of their entitlements (except by

sale through a broker)?

⁺Issue date

N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

Type of⁺securities

(tick one)

(a) x⁺Securities described in Part 1

(b)

All other⁺securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid,

employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible

securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or

documents

If the⁺securities are⁺equity securities, the names of the 20 largest holders of the

additional⁺securities, and the number and percentage of additional⁺securities

held by those holders

If the⁺securities are⁺equity securities, a distribution schedule of the additional

⁺securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

A copy of any trust deed for the additional⁺securities

+ See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 7

Appendix 3B

New issue announcement

Entities that have ticked box 34(b)

Number of⁺securities for which N/A

⁺quotation is sought

⁺Class of⁺securities for which N/A

quotation is sought

Do the⁺securities rank equally in N/A

all respects from the⁺issue date

with an existing⁺class of quoted

⁺securities?

If the additional⁺securities do not

rank equally, please state:

 the date from which they do

 the extent to which they

participate for the next

dividend, (in the case of a

trust, distribution) or interest

payment

 the extent to which they do

not rank equally, other than in

relation to the next dividend,

distribution

interest

payment

Reason for request for quotation N/A

now

Example: In the case of restricted securities, end

of restriction period

(if issued upon conversion of

another⁺security, clearly identify

that other⁺security)

Number

⁺Class

Number and

⁺class of all N/A

N/A

⁺securities quoted on ASX

(including the⁺securities in clause

38)

+ See chapter 19 for defined terms.

Appendix 3B Page 8

04/03/2013

Appendix 3B

New issue announcement

Quotation agreement

⁺Quotation of our additional⁺securities is in ASX’s absolute discretion. ASX

may quote the⁺securities on any conditions it decides.

We warrant the following to ASX.



The issue of the⁺securities to be quoted complies with the law and is

not for an illegal purpose.



There is no reason why those⁺securities should not be granted

⁺quotation.



An offer of the⁺securities for sale within 12 months after their issue

will not require disclosure under section 707(3) or section 1012C(6) of

the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be

able to give this warranty



Section 724 or section 1016E of the Corporations Act does not apply to

any applications received by us in relation to any⁺securities to be

quoted and that no-one has any right to return any⁺securities to be

quoted under sections 737, 738 or 1016F of the Corporations Act at the

time that we request that the⁺securities be quoted.



If we are a trust, we warrant that no person has the right to return the

⁺securities to be quoted under section 1019B of the Corporations Act at

the time that we request that the⁺securities be quoted.

We will indemnify ASX to the fullest extent permitted by law in respect of any

claim, action or expense arising from or connected with any breach of the

warranties in this agreement.

We give ASX the information and documents required by this form. If any

information or document is not available now, we will give it to ASX before

⁺quotation of the⁺securities begins. We acknowledge that ASX is relying on

the information and documents. We warrant that they are (will be) true and

complete.

Sign here:

............................................................

Date: 5^th of November

2013

(Director/Company secretary)

Print name:

Lionel Mateo

== == == == ==

+ See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 9

Appendix 3B

New issue announcement

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for

eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement

capacity is calculated

Insert number of fully paid⁺ordinary

103,805,676

securities on issue 12 months before the

⁺issue date or date of agreement to issue

Add the following:

34,470,357

• Number of fully paid⁺ordinary securities

issued in that 12 month period under an

exception in rule 7.2

• Number of fully paid⁺ordinary securities

issued in that 12 month period with

shareholder approval

• Number of partly paid⁺ordinary

securities that became fully paid in that

12 month period

Note:

• Include only ordinary securities here –

other classes of equity securities cannot

be added

• Include here (if applicable) the securities

the subject of the Appendix 3B to which

this form is annexed

• It may be useful to set out issues of

securities on different dates as separate

line items

Subtract the number of fully paid⁺ordinary

securities cancelled during that 12 month

period

“A”

138,276,033

+ See chapter 19 for defined terms.

Appendix 3B Page 10

04/03/2013

Appendix 3B

New issue announcement

Step 2: Calculate 15% of “A”

“B”

0.15

[Note: this value cannot be changed]

Multiply “A” by 0.15

20,741,405

Step 3: Calculate “C”, the amount of placement capacity under rule

7.1 that has already been used

Insert number of⁺equity securities issued

11,190,819

or agreed to be issued in that 12 month

period not counting those issued:

• Under an exception in rule 7.2

• Under rule 7.1A

• With security holder approval under rule

7.1 or rule 7.4

Note:

• This applies to equity securities, unless

specifically excluded – not just ordinary

securities

• Include here (if applicable) the securities

the subject of the Appendix 3B to which

this form is annexed

• It may be useful to set out issues of

securities on different dates as separate

line items

“C”

11,190,819

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining

placement capacity under rule 7.1

“A” x 0.15

20,741,405

Note: number must be same as shown in

Step 2

Subtract “C”

11,190,819

Note: number must be same as shown in

Step 3

Total [“A” x 0.15] – “C”

9,550,586

[Note: this is the remaining placement

capacity under rule 7.1]

+ See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 11

Appendix 3B

New issue announcement

Part 2

Rule 7.1A – Additional placement capacity for eligible entities

Step 1: Calculate “A”, the base figure from which the placement

capacity is calculated

“A”

N/A

Note: number must be same as shown in

Step 1 of Part 1

Step 2: Calculate 10% of “A”

“D”

0.10

Note: this value cannot be changed

Multiply “A” by 0.10

N/A

Step 3: Calculate “E”, the amount of placement capacity under rule

7.1A that has already been used

Insert number of⁺equity securities issued

N/A

or agreed to be issued in that 12 month

period under rule 7.1A

Notes:

• This applies to equity securities – not

just ordinary securities

• Include here – if applicable – the

securities the subject of the Appendix

3B to which this form is annexed

• Do not include equity securities issued

under rule 7.1 (they must be dealt with

in Part 1), or for which specific security

holder approval has been obtained

• It may be useful to set out issues of

securities on different dates as separate

line items

“E”

N/A

+ See chapter 19 for defined terms.

Appendix 3B Page 12

04/03/2013

Appendix 3B

New issue announcement

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining

placement capacity under rule 7.1A

“A” x 0.10

N/A

Note: number must be same as shown in

Step 2

Subtract “E”

N/A

Note: number must be same as shown in

Step 3

Total [“A” x 0.10] – “E”

N/A

Note: this is the remaining placement

capacity under rule 7.1A

+ See chapter 19 for defined terms.

04/03/2013

Appendix 3B Page 13